Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
I
287840
vs
K
KOSPI 200
Over the past 12 months, IntoCell Inc has underperformed KOSPI 200, delivering a return of -29% compared to KOSPI 200's +108% growth.
Stocks Performance
287840 vs KOSPI 200
Performance Gap
287840 vs KOSPI 200
Performance By Year
287840 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
IntoCell Inc
Glance View
IntoCell, Inc. engages in the research and development of ADC platform technology. The company is headquartered in Daejeon, Daejeon and currently employs 43 full-time employees. The company went IPO on 2025-05-23. The firm mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.